Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, announced new Phase 3b topline Week 16 results from Cohort A of the VISIBLE trial, the first prospective, large-scale, randomized-controlled ...

Please provide your email address to receive an email when new articles are posted on . Bimzelx (bimekizumab-bkzx) is the first and only interleukin 17A and 17F inhibitor approved in this indication.

Please provide your email address to receive an email when new articles are posted on . 85.1% of patients achieved PASI 90 and 52.3% achieved PASI 100 at week 256. The rates of treatment-emergent ...

The application is supported by data from the pivotal phase 3 POETYK PSO-1 and POETYK PSO-2, which included patients with moderate to severe plaque psoriasis. The Food and Drug Administration (FDA) ...

An improvement of 75% or greater in Psoriasis Area and Severity Index scores were achieved by week 12 of treatment among patients with moderate to severe plaque psoriasis receiving zasocitinib in ...

Icotrokinra achieved 75% complete skin clearance in adolescents with moderate to severe plaque psoriasis by week 24, indicating significant efficacy. The ICONIC-LEAD trial is the first to evaluate ...

With a low number of approved medications for pediatric plaque psoriasis, secukinumab is a valuable new addition to the limited treatment options available. Secukinumab is a valuable addition to the ...